BGM0504: A Next-Generation Dual GLP-1/GIP Peptide Designed to Outperform Tirzepatide
Using molecular simulations, researchers redesigned tirzepatide to create BGM0504, a dual GLP-1/GIP agonist with 2-3x greater potency while keeping the same long-lasting action.
Quick Facts
What This Study Found
BGM0504 achieved a 2-3 fold increase in agonistic activity at both GLP-1R and GIPR compared to tirzepatide, while maintaining equivalent extended plasma half-life, by repositioning the acylation side chain based on molecular dynamics insights.
Key Numbers
BGM0504 was optimized using molecular dynamics to achieve enhanced dual-target agonism at both GLP-1R and GIPR.
How They Did This
Molecular dynamics simulations to map peptide-receptor interactions, followed by structure-guided peptide optimization. Validated with in vitro receptor activation assays and in vivo animal studies comparing BGM0504 to tirzepatide.
Why This Research Matters
Tirzepatide is already one of the most effective diabetes and obesity drugs available. A peptide that is 2-3x more potent could mean lower doses, fewer side effects, or greater efficacy — potentially advancing the next generation of metabolic disease treatment.
The Bigger Picture
The race to improve upon GLP-1 drugs is intensifying. BGM0504 represents a computational approach to peptide drug design — using molecular simulations to find optimizations that traditional methods might miss. If clinical trials confirm these preclinical results, it could become a more potent alternative to tirzepatide.
What This Study Doesn't Tell Us
Preclinical data only — no human trials yet. In vitro and animal study results do not always translate to clinical superiority. The 2-3x potency increase in receptor activation may not produce proportionally better clinical outcomes. Safety profile in humans is unknown.
Questions This Raises
- ?Will BGM0504 show meaningful clinical advantages over tirzepatide in human trials?
- ?Does increased receptor potency translate to better weight loss and glycemic control, or just more side effects?
- ?How does BGM0504 compare to other next-generation dual and triple agonist peptides in development?
Trust & Context
- Key Stat:
- 2-3x more potent than tirzepatide at activating GLP-1 and GIP receptors, while maintaining the same long-lasting action
- Evidence Grade:
- Preliminary evidence: computational design validated by in vitro and animal studies. No human clinical trial data yet.
- Study Age:
- Published in 2024. Represents cutting-edge peptide drug design using computational methods.
- Original Title:
- Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.
- Published In:
- Scientific reports, 14(1), 16680 (2024)
- Authors:
- Yuan, Jiandong, Liu, Wenlang, Jiang, Xiaohui, Huang, Yangqing, Zong, Leilei, Ding, Haifeng, Shen, Xinyi, Sun, Yujia, Feng, Xiangyang, Li, Xionghao, Song, Yunsong, Gu, Jianing, Wang, Yuhuai, Liu, Hao, Zheng, Zheng
- Database ID:
- RPEP-09618
Evidence Hierarchy
Frequently Asked Questions
How is BGM0504 different from tirzepatide?
Both activate GLP-1 and GIP receptors, but BGM0504 has a repositioned chemical modification that allows 2-3 times stronger receptor activation without losing the long-lasting action. Think of it as the same key, resharpened to turn the lock more effectively.
When could BGM0504 become available?
It is currently in preclinical stages. If it advances to clinical trials and succeeds, it could be years before potential approval. However, its computational design approach may accelerate development compared to traditional drug discovery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09618APA
Yuan, Jiandong; Liu, Wenlang; Jiang, Xiaohui; Huang, Yangqing; Zong, Leilei; Ding, Haifeng; Shen, Xinyi; Sun, Yujia; Feng, Xiangyang; Li, Xionghao; Song, Yunsong; Gu, Jianing; Wang, Yuhuai; Liu, Hao; Zheng, Zheng. (2024). Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.. Scientific reports, 14(1), 16680. https://doi.org/10.1038/s41598-024-66998-8
MLA
Yuan, Jiandong, et al. "Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity.." Scientific reports, 2024. https://doi.org/10.1038/s41598-024-66998-8
RethinkPeptides
RethinkPeptides Research Database. "Molecular dynamics-guided optimization of BGM0504 enhances d..." RPEP-09618. Retrieved from https://rethinkpeptides.com/research/yuan-2024-molecular-dynamicsguided-optimization-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.